Acquisition Rumors Aren’t the Only Thing Moving Amarin Stock
It’s been three weeks since the U.S. Food and Drug Administration recommended that Amarin’s (NASDAQ:AMRN) prescription-strength fish oil drug, Vascepa, be approved for broader use to help patients at risk for heart and stroke problems. Amarin stock jumped on the news but has since fallen back into the low $20s. Source: Pavel Kapysh …
News story posted on 2019-12-08T00:00:00.0000000Z
